MDT Medtronic (MDT) Q1 FY26 earnings call
Medtronic delivered a consistent quarter of mid-single-digit organic revenue growth and exceeded EPS expectations, driven by strong performance in Cardiovascular and Neuromodulation. The company is confident in accelerating growth in the second half of FY26, fueled by key product launches in Cardiac Ablation, Renal Denervation, and Diabetes. Strategic initiatives, including the planned Diabetes separation and a new partnership with Elliott Management, aim to enhance focus on growth and operational efficiency, positioning Medtronic for durable, higher earnings growth and long-term shareholder v
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
MDT operating KPIs by quarter
| KPI | Jan 2026 Q3 FY26 | Apr 2026 Q4 FY26 | Jul 2026 Q1 FY27 | Change vs prior quarter |
|---|---|---|---|---|
| Installed base Touch Surgery | 1,000+This quarter, Touch Surgery installations increased over 20% sequentially and have now surpassed 1,000 systems globally.Source: earnings call transcript | 1,400+And our Touch Surgery Digital Ecosystem, well, it continues to represent a clear advantage with over 1,400 installations, up 30% plus sequentially.Source: earnings call transcript | 1,500+Today, Touch Surgery is used in more than 1,500 operating rooms globally, supporting AI-powered insights, collaboration and workflows.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.